Allarity Therapeutics Aktie Logo
US0167445008

Allarity Therapeutics Aktie

Ins Portfolio
Kostengünstig und breit gestreut in Europa investieren. Jetzt entdecken
Anzeige

Kurse werden geladen...

Prognose

Kaufen
  0
Halten
  1
Verkaufen
  0

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News


  • Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

    TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology, today announced the appointment of Jeff Ervin as the Company's new Chief Financial Officer (CFO).» Mehr auf globenewswire.com


  • Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

    TARPON SPRINGS, Fla., June 27, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor today announced that the second patient has been dosed in its new Phase 2 clinical trial protocol evaluating stenoparib in patients with advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer.» Mehr auf globenewswire.com


  • Allarity Therapeutics Announces Changes to Board of Directors

    TARPON SPRINGS, Fla., June 11, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced that Jesper Høiland has been appointed to join the Company's Board of Directors. He will be replacing Joseph Vazzano, who will resign from the Board effective on June 30, 2025, following his valuable contributions to Allarity's development over the past two years.» Mehr auf globenewswire.com

Unternehmenszahlen

Im letzten Quartal hatte Allarity Therapeutics Aktie einen Umsatz von 0,00 und ein Nettoeinkommen von 2,53 Mio
(EUR)März 2025
YOY
Umsatz0,00-
Bruttoeinkommen0,00100,00%
Nettoeinkommen2,53 Mio29,08%
EBITDA2,81 Mio19,08%

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+13,50 Mio
Anzahl Aktien
15,08 Mio
52 Wochen-Hoch/Tief
+6,34 - +0,52
DividendenNein
Beta
-0,15
KGV (PE Ratio)
0,05
KGWV (PEG Ratio)
0,00
KBV (PB Ratio)
+0,06
KUV (PS Ratio)
0,00

Unternehmensprofil

Name
Allarity Therapeutics Aktie
CEO
Thomas H. Jensen
Mitarbeiter6
🍪

Parqet nutzt Cookies.Erfahre Mehr